IL-6 Inhibition as a Treatment for Noninfectious Uveitis - Summary - MDSpire

IL-6 Inhibition as a Treatment for Noninfectious Uveitis

Understanding interleukin-6 signaling sheds light on novel biologics that could benefit patients with refractory NIU.

  • By

  • Naveen Karthik, MD

  • Dilraj S. Grewal, MD, FASRS

  • September 1, 2025

  • 12 min

Share

Objective:

To explore the role of IL-6 as a therapeutic target and review current IL-6 inhibitor therapies for noninfectious uveitis (NIU), highlighting its significance in treatment.

Approach:
    Key Findings:
    • Tocilizumab has shown efficacy in treating refractory NIU and associated cystoid macular edema, as demonstrated in the STOP-Uveitis trial.
    • Clinical trials demonstrated significant improvement in best-corrected visual acuity (BCVA) and reduction in central macular thickness with tocilizumab, particularly in multicenter studies.
    • Sarilumab also resulted in significant decreases in vitreous haze and improved BCVA compared to placebo, as shown in the SATURN study.
    Interpretation:

    IL-6 inhibitors represent a promising therapeutic option for patients with refractory NIU, potentially improving visual outcomes and reducing inflammation, though further research is essential.

    Limitations:
    • Limited long-term safety data for IL-6 inhibitors in uveitis, with variability in patient response and potential adverse effects such as infections.
    Conclusion:

    IL-6 inhibition is a viable treatment strategy for noninfectious uveitis, with ongoing research needed to further establish efficacy and safety, particularly regarding long-term outcomes.

Original Source(s)

IL-6 Inhibition as a Treatment for Noninfectious Uveitis

  • by Naveen Karthik, MD, Dilraj S. Grewal, MD, FASRS

  • September 1, 2025

Related Content

Targeting IL-6 in the Treatment of Uveitic Macular Edema

New Target for Uveitis Therapy

Could targeting cGAS-STING represent a new treatment avenue for uveitis?

  • May 21, 2026

  • 3 min
Treatment Strategies in Endogenous Fungal Endophthalmitis

Management of endogenous fungal endophthalmitis is complex, with wide variation in treatment strategies. Systemic markers of disease appear to influence the choice of initial therapy more than ocular findings. Although no definitive evidence favors IV over oral systemic therapy, a comprehensive, multidisciplinary approach that considers ocular involvement is essential to optimize patient outcomes in EFE.